Sofpironium bromide explained
| Tradename: | Ecclock, others |
| Dailymedid: | Sofpironium bromide |
| Routes Of Administration: | Topical |
| Class: | Anticholinergic |
| Atc Prefix: | None |
| Legal Us: | Rx-only |
| Legal Us Comment: | [1] |
| Legal Status: | JP: Rx-only |
| Cas Number: | 1628106-94-4 |
| Pubchem: | 86301316 |
| Drugbank: | DB19325 |
| Chemspiderid: | 52085312 |
| Unii: | 7B2Y1932XU |
| Kegg: | D10989 |
| Chembl: | 3707223 |
| Synonyms: | BBI-4000, BBI 4000 |
| Iupac Name: | [(3''R'')-1-(2-Ethoxy-2-oxoethyl)-1-methylpyrrolidin-1-ium-3-yl] (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetate bromide |
| C: | 22 |
| H: | 32 |
| Br: | 1 |
| N: | 1 |
| O: | 5 |
| Smiles: | CCOC(=O)C[N+]1(CC[C@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C.[Br-] |
| Stdinchi: | 1S/C22H32NO5.BrH/c1-3-27-20(24)16-23(2)14-13-19(15-23)28-21(25)22(26,18-11-7-8-12-18)17-9-5-4-6-10-17;/h4-6,9-10,18-19,26H,3,7-8,11-16H2,1-2H3;1H/q+1;/p-1/t19-,22+,23?;/m1./s1 |
| Stdinchikey: | FIAFMTCUJCWADZ-JOFREBOKSA-M |
Sofpironium bromide, sold under the brand name Ecclock among others, is a medication used to treat hyperhidrosis (excessive sweating). Sofpironium bromide is an anticholinergic agent that is applied to the skin.
It was approved in Japan in 2020, for the treatment of primary axillary hyperhidrosis.[2] It was approved for medical use in the United States in June 2024.[3] [4]
Medical uses
Sofpironium bromide is indicated for the treatment of primary axillary hyperhidrosis.
Mechanism of action
The pharmacodynamics of sofpironium bromide are unknown.
Society and culture
Legal status
It was approved for medical use in Japan in November 2020,[5] and in the United States in June 2024.[6]
Brand names
Sofpironium bromide is the international nonproprietary name.[7]
It is sold under the brand name Ecclock in Japan and under the brand name Sofdra in the US.
Further reading
- Yokozeki H, Fujimoto T, Abe Y, Igarashi M, Ishikoh A, Omi T, Kanda H, Kitahara H, Kinoshita M, Nakasu I, Hattori N, Horiuchi Y, Maruyama R, Mizutani H, Murakami Y, Watanabe C, Kume A, Hanafusa T, Hamaguchi M, Yoshioka A, Egami Y, Matsuo K, Matsuda T, Akamatsu M, Yorozuya T, Takayama S . A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis . The Journal of Dermatology . 48 . 3 . 279–288 . March 2021 . 33410265 . 7986147 . 10.1111/1346-8138.15668 .
External links
Notes and References
- Web site: Sofdra- sofpironium bromide gel . DailyMed . 26 August 2024 . 2 September 2024.
- Paik J . Sofpironium Bromide: First Approval . Drugs . 80 . 18 . 1981–1986 . December 2020 . 33236266 . 10.1007/s40265-020-01438-1 . 227155835 .
- Web site: Drug Approval Package: Sofdra . U.S. Food and Drug Administration (FDA) . 17 July 2024 . 2 September 2024.
- FDA Approves Sofdra topical gel . Botanix Pharmaceuticals . 20 June 2024 . 20 June 2024 . 20 June 2024 . https://web.archive.org/web/20240620230416/https://botanixpharma.com/fda-approves-sofdra-topical-gel/ . live .
- Brickell Biotech Announces Launch Date for Sofpironium Bromide Gel, 5% (Ecclock) in Japan by its Development Partner, Kaken Pharmaceutical . Brickell Biotech . GlobeNewswire . 18 November 2020 . 2 September 2024.
- Web site: Novel Drug Approvals for 2024 . U.S. Food and Drug Administration (FDA) . 1 October 2024 . 29 November 2024.
- ((World Health Organization)) . 2017 . International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 77 . WHO Drug Information . 31 . 1 . 10665/330984 . free . World Health Organization .
